Content Conference Coverage Conferences AASLD 2016
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Created on Sunday, 20 November 2016 00:00
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/20/16
AASLD 2016: Tenofovir Alafenamide Approved for Hepatitis B, Works Well with Less Effect on Bones
- Details
- Category: Approved HBV Drugs
- Created on Monday, 14 November 2016 00:00
Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus but causes less bone mineral loss, according to a report at the AASLD Liver Meeting this week in Boston. The U.S. Food and Drug Administration last week approved stand-alone TAF for hepatitis B treatment.
AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Created on Wednesday, 30 November 2016 00:00
An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well-tolerated, but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, according to a study reported at the AASLD Liver Meeting this month in Boston.
AASLD 2016: Lonafarnib Lowers Hepatitis Delta Levels with Acceptable Side Effects
- Details
- Category: Experimental HBV Drugs
- Created on Monday, 23 January 2017 00:00
The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal side effects, according to study results presented at the recent AASLD Liver Meeting in Boston.
AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- Details
- Category: Experimental HBV Drugs
- Created on Tuesday, 22 November 2016 00:00
The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small study presented as a late-breaker at the AASLD Liver Meeting this month in Boston. This combination may potentially enable functional control of hepatitis B if confirmed in larger studies.
More Articles...
- AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?
- AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- AASLD 2016: Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals 12 Weeks for Many Patients
- AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens
- AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
- AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression
- AASLD 2016: 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C
- AASLD 2016: Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure
- AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C
- AASLD 2016: U.S. Veterans Health System and Australia Show Potential for Rapid Hepatitis C Elimination
- AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients
- AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results
- AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed
- AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients
- AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C
- AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes
- AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3
- AASLD 2016: Hepatitis C Virus Infections Rising Among HIV+ Gay Men in San Diego
- AASLD 2016: Birth Cohort Screening and Linkage to Hepatitis C Care Still Weak in U.S.
- AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
- AASLD 2016: Curing Hepatitis C Reduces Liver-Related Complications and Death
- AASLD 2016: Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C
- AASLD 2016: Portal Hypertension Less Likely to Improve After HCV Treatment When Fibrosis Is Severe
- AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts
- AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid
- AASLD 2016: When You Eat May Contribute to Fatty Liver Disease as Much as What You Eat
Web Design and Development by